Keynote Lectures

State-of-Art Lecture

Global Elimination of Hepatitis B: Taiwan Experiences and International Collaborations

Chien-Jen Chen
Taipei

Chairman Lecture

Towards Hepatitis B Elimination: Taiwan Experience

Rong-Nan Chien
Taoyuan

KL1

HBeAg-negative Chronic HBV Infection: Natural Course and Management in the Light of HBsAg Quantification

Yun-Fan Liaw
Taoyuan

KL2

Toward Global Elimination of Hepatitis B

Anna Suk-Fong Lok
Ann Arbor

KL3

Research on HBV Life Cycle and Drug Discovery

Takaji Wakita
Tokyo

Special Lecture

Human Genomics and Hepatitis B

Masashi Mizokami
Ichikawa

Plenary Sessions

PL1-1

Natural History of Acute and Chronic HBV Infection

Chia-Ming Chu
Taoyuan

PL1-2

Epidemiology and Clinical Significance of Occult HBV Infection

Giovanni Raimondo
Messina

PL1-3

Pathway from the Epidemiological Point of View; Moving towards the Elimination of HBV & HCV in Japan

Junko Tanaka
Hiroshima

PL1-4

Global Epidemiology and Prevention of Chronic Hepatitis B Infection

John Ward
Atlanta

PL2-1

Cell Entry Inhibition as an Antiviral Strategy

Koichi Watashi
Tokyo

PL2-2

Complete and Incomplete HBV Particles

Jianming Hu
Hershey

PL2-3

Recent Development of Capsid Modulators/ Inhibitors as New Antiviral Agents

Man-Fung Yuen
Hong Kong

PL2-4

Eliminating cccDNA: Methods and Difficulties

Chau-Ting Yeh
Taoyuan

PL3-1

The Liver Microenvironment and HBV Immunity

Percy A. Knolle
Munich

PL3-2

Manipulation of the Innate-adaptive Immune Cell Axis in Chronic HBV Infection

Laura Pallett
London

PL3-3

Cure CHB via Targeting Adaptive Immune Response: Animal Experience

Mi-Hua Tao
Taipei

PL3-4

T Cell Therapy for Chronic HBV Infection

Antonio Bertoletti
Singapore

PL4-1

Epidemiology and Risk Assessment of Hepatitis C virus Infection in Taiwan

Mei-Hsuan Lee
Taipei

PL4-2

Current Treatment of HCV

Chen-Hua Liu
Taipei

PL4-3

Unmet Needs of Chronic Hepatitis C after SVR

Ming-Lung Yu
Kaohsiung

PL4-4

How to Achieve Global HCV Elimination by 2030?

Geoffrey Dusheiko
London

PL5-1

Advances in the Serologic and Virologic Diagnosis of HBV Infection

Yasuhito Tanaka
Nagoya

PL5-2

Application of Circulating DNA to HBV Induced Liver Pathogenesis

Shiou-Hwei Yeh
Taipei

PL5-3

Application of HCC Risk Scores in Management of CHB Patients

Hwai-I Yang
Taipei

PL5-4

Non-invasive Prediction of HBV Treatment Outcomes Including HCC

Grace Wong
Hong Kong

PL6-1

HDV Virology and The Novel Therapy for Chronic Hepatitis D

Camille Sureau
Paris

PL6-2

Mechanisms of Large Hepatitis Eelta Antigen Induced Epithelial-mesenchymal Transition: Implications of Novel Therapy

Jaw-Ching Wu
Taipei

PL6-3

Taiwan-Mongolian Collaboration to Control HDV Infection in a Hyperendemic Area

Davaadorj Duger
Ulaanbaatar

PL6-4

Natural History of Chronic Hepatitis D Virus Infection

Chien-Wei Su
Taipei

PL7-1

Unmet Needs of CHB after NUC Treatment

Henry Lik-Yuen Chan
Hong Kong

PL7-2

Management of CHB Sub-populations with Grey Zone Treatment Indications

Tai-Chung Tseng
Taipei

PL7-3

NUC for CHB: Discontinued Versus Continuous Strategy

Yi-Cheng Chen
Taoyuan

PL7-4

Reactivation of HBV in Special Clinical Settings: Risk and Management

Chun-Jen Liu
Taipei

PL8-1

Advance in Radiofrequency Ablation Therapy for HCC

Ryosuke Tateishi
Tokyo

PL8-2

Advance in Drug-elution Bead TACE and SIRT for HCC

Yoon-Jun Kim
Seoul

PL8-3

Proton Beam Therapy for HCC

Ji-Hong Hong
Taoyuan

PL8-4

Advance in Immune Checkpoint Inhibitors for HCC

Ann-Lii Cheng
Taipei

PL9-1

Global Strategies of Hepatitis B Vaccination: The Past, Present and Future

Mei-Hwei Chang
Taipei

PL9-2

The Implementation of HBV Vaccination in SouthEast Asia

Yong Poovorawan
Bangkok

PL9-3

How to Convince People to Implement Universal Vaccination in a Low-endemic Area?

Ayano Inui
Yokohama

PL9-4

Elimination of Mother-to-Child Transmission of HBV

Huey-Ling Chen
Taipei

Guidelines Workshop

IG-01

The Hong Kong Situation

Vincent Wai-sun Wong
Hong Kong

IG-02

The JSH Guideline for the Antiviral Treatment of Hepatitis B Virus Infection and Current Issues in Japan

Tetsuya Hosaka
Tokyo

IG-03

Korean Guideline and Reimbursement Policy on HBV

Young-Suk Lim
Seoul

IG-04

Current State of Hepatitis B in the Philippines

Stephen N. Wong
Manila

IG-05

Update Reimbursement Guidelines of HBV Therapy in Taiwan and the Long-term Outcomes

Jia-Horng Kao
Taipei

IG-06

Management of Hepatitis B in India: Current Guidelines

Anil Arora
New Delhi

IG-07

A Community Based Hepatitis B Programme in New Zealand to Eliminate Hepatitis B

Susan Hay
Whakatane

IG-08

Simplifying “CHB” Terminology in the Hepatitis B Treatment Guidelines

Rosmawati Mohamed
Kuala Lumpur

IG-09

The Evolving HBV Guidelines and Reimbursement Policies in Mainland China

Jidong Jia
Beijing

IG-10

Armenian Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection

Hasmik Ghazinyan
Yerevan

Post-Graduate Course

PG1-1

Experience from HCV Cure

Chen-Hua Liu
Taipei

PG1-2

Current Strategy for HBV Treatment: Benefit and Challenge

Chien-Hung Chen
Kaohsiung

PG1-3

Hepatitis B Virus Infection and Liver Carcinogenesis

Shiou-Hwei Yeh
Taipei

PG1-4

Clinical and Virological Significance of NTCP Receptor in HBV

Koichi Watashi
Tokyo

PG2-1

Overview of HBV Molecular Virology - Unsolved Issues and New Drug (Targets)

Man-Fung Yuen
Hong Kong

PG2-2

Overview of HBV Immunology

Mi-Hua Tao
Taipei

PG2-3

Prospect for the HBV Therapy from the Immunological Approach

Antonio Bertoletti
Singapore

PG2-4

Issues after Hepatitis B Cure --- HBV Reactivation

Yasuhito Tanaka
Nagoya

Moderators

PL3

Antonio Bertoletti
Singapore

YIA / PL7

Henry Lik-Yuen Chan
Hong Kong

KL2

Mei-Hwei Chang
Taipei

State-of-Art Lecture

Ding-Shinn Chen
Taipei

YIA / KL3

Pei-Jer Chen
Taipei

PG1 / Presidential-Oral

Wan-Long Chuang
Kaohsiung

PG2

Chia-Yen Dai
Kaohsiung

PL4 / Presidential- Oral

Geoffrey Dusheiko
London

PL8

Yi-Hsiang Huang
Taipei

PL4 / Special Lecture

Jia-Horng Kao
Taipei

Chairman Lecture / IG

Yun-Fan Liaw
Taoyuan

PG1

Han-Chieh Lin
Taipei

PL3

Chun-Yen Lin
Taipei

PL5 / PL7

Chun-Jen Liu
Taipei

IG

Anna Suk-Fong Lok
Ann Arbor

PL1

Sheng-Nan Lu
Chiayi

PL2

Masashi Mizokami
Ichikawa

PL9

Yen-Hsuan Ni
Taipei

KL1 / IG

Masao Omata
Kofu

PL9

Yong Poovorawan
Bangkok

PG2

ChiaHo Shih
Taipei

PL6

Camille Sureau
Paris

PL1

Junko Tanaka
Hiroshima

PL5

Yasuhito Tanaka
Nagoya

PL8

Ryosuke Tateishi
Tokyo

PL6

Jaw-Ching Wu
Taipei

PL2

Chau-Ting Yeh
Taoyuan